Latest news for Orexo (OTC:ORXOY) Stock

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Biotech

News

Penny Stocks

Health Care

General

INVVY

IZQVF

ORXOF

ORXOY

The FDA warned patients and prescribers about the risk of potential dental problems arising from the us

Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags

Movers & Shakers

Small Cap

Events

Global

Markets

Trading Ideas

ETFs

BNIGF

EMMA

LXRP

MBRX

NRIFF

RDHL

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences

Orexo AB

Jesus Christ and his apostles could have used a cannabis-based anointing oil to help heal people with disabling diseases. A study exploring biblical texts has sparked a provocative discussion about the potential use of <a href="https://www.benzinga.com/topic/cannabis-news">cannabis</a> in ancient religious practices, specifically those associated with Jesus and his disciples. This research indicates that cannabis was likely a key ingredient in the anointing oils used during biblical times, supporting claims that Jesus may have utilized the plant for its medicinal properties.
<h3 class="wp-block-heading">Cannabis In Biblical Anointing Oils</h3>
According to Chris Bennett, <a href="https://archive.hightimes.com/article/2003/2/1/was-jesus-a-stoner">writing</a> for High Times, the substance known as kaneh-bosem, referenced in scripture, is now believed to be cannabis extract. Bennett cites various scholars who support this claim, suggesting that the oils used for anointing during Jesus&#8217; time contained this potent substance. "There can be little doubt about a role for cannabis in Judaic religion," Carl Ruck, a professor of classical mythology at Boston University, told The Guardian. Ruck elaborated: "Obviously the easy availability and long-established tradition of cannabis in early Judaism would inevitably have included it in the [Christian] mixtures."
Bennet recovered the research of Polish anthropologist <a href="https://findingaids.library.nyu.edu/archives/rism_rg_2/">Sula Benet</a>, who in 1936 discovered the translation error in the Old Testament, and then demonstrated in her essays "Tracing One Word Through Different Languages" (1936) and "<a href="https://www.xn--4dbcyzi5a.com/wp-content/PDF/EARLY-DIFFUSION-AND-FOLK-USES-OF-HEMP-SULA-BENET.pdf">Early Diffusions and Folk Uses of Hemp</a>" (1975), that the Hebrew terms "kaneh" and "kaneh-bosm" identified cannabis.
<h3 class="wp-block-heading">Healing Practices And Miraculous Effects</h3>
The research posits that the anointing oils not only played a ceremonial role but also served practical healing purposes. Bennett argued that those anointed with these oils were "literally drenched in this potent mixture." While many contemporary cannabis users prefer smoking or <a href="https://www.benzinga.com/topic/cannabis-edibles">ingesting</a> the plant, the ancient method of oil infusion allowed for absorption through the skin, potentially enhancing its <a href="https://www.benzinga.com/topic/medical-cannabis">therapeutic effects.</a>
Bennett drew connections between these practices and the healing miracles attributed to Jesus in the Gospels, particularly those involving skin and eye diseases. "If cannabis was one of the main ingredients of the ancient anointing oil, and receiving this oil is what made Jesus the Christ and his followers Christians, then persecuting those who use cannabis could be considered anti-Christ," he concluded.
<h3 class="wp-block-heading">Implications For Modern Perspectives On Cannabis</h3>
This perspective invites a reevaluation of how cannabis is viewed in both historical and contemporary contexts. As public opinion shifts toward more favorable views on cannabis, the implications of these findings could influence discussions about its place in religious and therapeutic practices today.
With ongoing debates about <a href="https://www.benzinga.com/topic/cannabis-legalization">cannabis legalization</a> and its medicinal benefits, the intersection of ancient traditions and modern science may help reshape conversations surrounding this historically significant plant.
Cover image made with AI

Cannabis

Psychedelics

Was Cannabis The Secret To Jesus' Healing Miracles? Study Uncovers Ancient Remedies

The announcement that Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is bringing in Elliot Hill as the new CEO could be a positive change given his experience and company tenure, but it raises questions about the company&#8217;s strategy for a turnaround and plans to return to revenue growth.
The Nike Analysts: 
<ul>
<li>Piper Sandler analyst Anna Andreeva maintained a Neutral rating with a $80 price target.</li>
<li>KeyBanc analyst Ashley Owens maintained a Sector Weight rating with no price target.</li>
<li>Stifel analyst Jim Duffy maintained a Hold rating with a $79 price target.</li>
<li>BMO analyst Simeon Siegel reiterated an Outperform rating with a $92 price target.</li>
<li>Truist analyst Joseph Cirello maintained a Hold rating and raised the price target from $81 to $85.</li>
<li>RBC Capital analyst Piral Dadhania maintained a Sector Perform rating with a $75 price target.</li>
<li>JPMorgan analyst Matthew Boss maintained a Neutral rating with an $83 price target.</li>
</ul>
Piper Sandler on NKE: Nike's announcement is a positive for the stock, Andreeva said in a new investor note.
"This removes an overhang in leadership and creates a potentially interesting setup with the Investor Day in November," Andreeva said.
The analyst said that the announcement came sooner than expected, adding that a CEO with deep company experience could positively impact the company culture.
While the news is positive for the stock, Andreeva said Nike could stay "range-bound" until more color is provided on the company's new strategy.
KeyBanc on NKE: With a combined 32 years of experience in various roles at Nike, Hill could play a key role in driving growth at the company, Owens said.
"We view Hill's longstanding connection with the company and expertise within the marketing scope as encouraging, as NKE examines reinvigorating brand storytelling," Owens said.
Stifel on NKE: Bringing back a long-time Nike insider is viewed as a positive by Duffy.
"Recent underperformance is a direct result of losing focus on what has made Nike great for so many years," Duffy said. "Under Mr. Hill's leadership, we hope to see a revitalization of the Nike culture and a renaissance in innovation and design."
The analyst warns that changing CEOs can reset financial forecasts, trigger periods of product revitalization, and potentially lead to additional management changes.
Duffy added that timing the change ahead of Nike's November Investor Day is "purposefully" planned and could offer a clearer view of the company&#8217;s future direction.
BMO Capital on NKE: The hiring of Hill could bring an immediate morale boost to Nike thanks to being well-liked by employees and retail partners, Siegel said in a new investor note.
The analyst said that CEO changes often take time to yield results, but Hill could help Nike regain success in areas such as product development and marketing.
"A new CEO changes the dynamic for the upcoming analyst day and we believe breathes new life and hope into a semi-abandoned blue-chip company in an environment where investors are looking for exactly that," Siegel said.
Read Also: <a href="https://www.benzinga.com/news/24/09/40957353/nikes-new-ceo-elliott-hill-to-focus-on-repairing-retailer-relations">Nike&#8217;s New CEO Elliott Hill To Focus On Repairing Retailer Relations</a>
Truist on NKE: Cirello cautions that the near-term upside for Nike could be limited after shares jumped on news of Hill's hiring.
The analyst said shares trade at price to earnings multiples of 25X or higher for fiscal year 2025 and 2026 estimates, "despite no projected revenue growth."
A leadership change could offer a better chance at a turnaround, but could be a long process, Cirello added.
"We view the move as a step in the right direction that can help reinvigorate the brand and improve sentiment on the stock, given that Mr. Hill is very well-respected and knows the business well from his 32-year Nike tenure," Cirello said.
Cirello said there could be "a long road ahead with a lot of potential bumps in the road."
RBC Capital on NKE: Given the recent struggles in share price, the announcement of a new CEO at Nike is a welcome development, Dadhania said in a recent investor note.
"Nike CEO change is unlikely to surprise the market, given investor discontent with the overall management and direction of the business in recent years, as well as increasing competition from newer players and incumbents," Dadhania said.
The analyst said Hill understands Nike's history, Nike's culture and the sportswear market, which could be a winning combination.
"We think this was the icing on the cake that the Nike bulls have been waiting for."
Goldman Sachs on NKE: Roach said in a note Thursday that Hill's background with Nike could be a key strength in helping with the company's turnaround.
"We are encouraged by today's announcement and are pleased that NKE's next CEO has a deep-rooted understanding of NKE culture, storytelling, and marketplace," Roach said.
Hill's comment on looking forward to delivering bold and innovative products caught the attention of the analyst and could be a positive ahead of the Investor Day.
"We look for initial thoughts from Mr. Hill regarding his initial priorities and an articulation of the updated NKE strategy, including channel and marketplace, innovation, demand creation, and opportunities to accelerate momentum in a competitive marketplace."
JPMorgan on NKE: Elliott's expertise and leadership style were credited with winning the CEO job, Boss said.
The analyst highlighted Nike's history with long-tenured managers as part of "the old guard."
"This represents a shift back to a seasoned Nike veteran as CEO with Hill having spent more than 32 years at Nike in various leadership roles, akin to Chairman and former CEO Mark Parker's resume of spending 27 years at Nike prior to his CEO appointment in 2006," Boss said.
Parker helped Nike produce high-single-digit revenue growth and mid-teens earnings per share growth, the analyst added.
NKE Price Action: Nike shares are up 6% to $86.17 on Friday versus a 52-week trading range of $70.75 to $123.39. Nike stock is down 19% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/06/39536852/nike-q4-earnings-highlights-revenue-miss-eps-beat-taking-our-near-term-challenges-head-on">Nike Q4 Earnings Highlights: Revenue Miss, EPS Beat, &#8216;Taking Our Near-Term Challenges Head-On&#8217;</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Analyst Color

Price Target

Reiteration

Analyst Ratings

Nike CEO Announcement 'Icing On The Cake' For Bulls: 8 Analysts React To Elliot Hill's Ascension

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) investors are bracing for a significant shake-up as the quarterly rebalancing of market index funds coincides with a rare triple witching event, a financial phenomenon that only intensifies market volatility.
<h2 class="wp-block-heading">Busiest Rebalancing In Four Years To Boost Apple </h2>
With $250 billion in stock adjustments underway, the iPhone manufacturer could emerge as one of the biggest beneficiaries. 
A notable shift comes from Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) trimming its stake, increasing the share count used by index providers to determine Apple's weight, pushing the Cupertino, California-based company&#8217;s stock to the top of S&amp;P 500 tracking funds.
<h2 class="wp-block-heading">Apple To Take The Lead Over Microsoft</h2>
Apple&#8217;s market capitalization of $3.48 trillion now surpasses Microsoft Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) $3.26 trillion, positioning the tech titan to be the largest holding in the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
As funds rebalance, a hefty $35 billion worth of Apple shares will need to be bought, which could provide significant support to its stock price. This reshuffling may further amplify the bullish momentum Apple has enjoyed year-to-date, with the stock already up over 24%.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40940715/apple-revenue-growth-just-too-slow-for-investors-to-get-excited-about-analyst-highl">Apple Revenue Growth &#8216;Just Too Slow For Investors To Get Excited About&#8217;: Analyst Highlights Advertising As Future Catalyst</a>
<h2 class="wp-block-heading">Bullish Signals All-Around</h2>
Apple&#8217;s stock chart is radiating strength, signaling continued bullish action.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM.png" alt="" class="wp-image-558956" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
With the stock trading above key moving averages — five, 20 and 50 days — the technical setup strongly favors buyers. The share price of $231.12 sits comfortably above its eight-day SMA of $221.71 and 20-day SMA of $223.84, offering a consistent bullish signal across multiple indicators.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM.png" alt="" class="wp-image-558957" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The Moving Average Convergence Divergence (MACD) suggests more buying pressure with a positive reading, while the Relative Strength Index (RSI) of 63.00 (and rising) indicates that although Apple is nearing overbought territory, the bullish momentum remains intact.
With the rebalancing aligning with positive technicals, investors are betting that Apple could soar further.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40958207/how-apple-stock-could-gain-from-fridays-s-p-500-rebalancing-what-investors-should-know">How Apple Stock Could Gain From Friday&#8217;s S&amp;P 500 Rebalancing: What Investors Should Know</a></li>
</ul>

Long Ideas

Technicals

Tech

AAPL

MSFT

Apple Vs. Microsoft: Can A $35B Rebalance Amplify Bullish Momentum?

Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) revealed the highly anticipated Silent Hill 2 remake would remain a PlayStation 5 console exclusive for one year, with other platforms not receiving the game until at least<a href="https://www.benzinga.com/general/gaming"> Oct. 8, 2025. </a>
Fans of the psychological horror classic have been eagerly awaiting this remake, developed by Bloober Team, which promises to retain the eerie charm of the 2001 original while introducing several new gameplay elements.
See Also: <a href="https://www.benzinga.com/general/gaming/24/09/40947591/playstation-celebrates-30-years-with-retro-themed-ps5-pro-and-slim-editions">PlayStation Celebrates 30 Years With Retro-Themed PS5 Pro And Slim Editions</a>
<h1 class="wp-block-heading">Exclusive PS5 Features</h1>
The announcement, first <a href="https://www.eurogamer.net/silent-hill-2-remake-will-be-a-ps5-console-exclusive-for-one-year">spotted</a> by Eurogamer in a new PlayStation trailer, confirms the remake will launch on both PC and PS5 on Oct. 8, 2024.
Players on other consoles, such as Xbox Series X&#x7C;S or Nintendo's next-gen console (potentially dubbed the Switch 2), will have to wait a full year for access. 
Sony has also confirmed full support for the PS5's DualSense controller in the Silent Hill 2 remake, taking advantage of its unique features like haptic feedback, adaptive triggers, and a dynamic lightbar.
<h1 class="wp-block-heading">Staying True to the Original with Modern Gameplay Enhancements</h1>
The Silent Hill 2 remake reimagines one of the most beloved psychological horror games of all time. The story follows James Sunderland, who receives a cryptic letter from his deceased wife, Mary, urging him to return to the eerie town of Silent Hill. 
As players guide James through the monster-infested town, they must piece together the unsettling mystery, all while facing a slew of terrifying foes.
Despite the introduction of modern gameplay mechanics, Bloober Team has remained adamant that the game's narrative will remain faithful to the 2001 original. 
However, they estimate players will take around 16 to 18 hours to complete the game, a noticeable increase from the original. This extended playtime is due to the revamped gameplay rather than any changes in the storyline.
Earlier this month, footage of the first 90 minutes of gameplay surfaced online, showcasing just under 10% of the game. 
For those looking to experience Silent Hill 2 with the highest possible fidelity, the game will also be compatible with the upcoming PS5 Pro, launching on Nov. 7, 2024. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40907983/september-playstation-plus-lineup-whats-coming-and-whats-leaving">September PlayStation Plus Lineup: What&#8217;s Coming And What&#8217;s Leaving</a></li>
</ul>
Photo: Courtesy of Bloober Team.

Gaming

Sony Group Corporation American Depositary Shares

SONY

Silent Hill 2 Remake Locks In PS5 Exclusivity For One Year

Offerings

BANL

CBL International Says May Offer & Sale From Time To Time In One Or More Offerings By Selling Securityholder Of Up To 2.5M Ordinary Shares

Yesterday, Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) reported first-quarter adjusted earnings per share of $1.75, missing&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40943086/darden-misses-q1-earnings-estimates-partners-with-uber-for-delivery-expansion" rel="noreferrer noopener">the analyst consensus estimate of $1.83.&nbsp;</a>Quarterly sales of $2.76 billion missed the street view of $2.80 billion.
Analysts covering <a target="_blank" href="https://www.benzinga.com/quote/DRI/analyst-ratings" rel="noreferrer noopener">the company provided their takes:</a>
<ul>
<li>KeyBanc Capital Markets analyst Eric Gonzalez reiterated the Overweight rating on the stock, raising the price forecast to $194 from $170.</li>
<li>BMO Capital Markets analyst Andrew Strelzik maintained the Market Perform rating, raising the price forecast to $175 from $165.</li>
<li>Wedbush analyst Nick Setyan reiterated the Outperform rating on Darden Restaurants, raising the price forecast to $200 from $170.</li>
<li>Piper Sandler analyst Brian Mullan reiterated the Neutral rating on the company, raising the price forecast to $177 from $159.</li>
<li>Truist Securities analyst Jake Bartlett maintained the Buy rating, increasing the price forecast to $195 from $185.</li>
</ul>
KeyBanc Capital Markets: The analyst anticipates potential growth from Darden&#8217;s partnership with Uber. Gonzalez also slightly raised the FY25 EPS estimate to $9.48, attributing this adjustment to a modest increase in blended same-store sales growth as Darden focuses more on price point advertising at Olive Garden. Darden will test delivery at approximately 100 Olive Garden locations during the holiday season, with plans to expand to the entire Olive Garden network by the end of FY25. It&#8217;s important to note that delivery menu prices will match those for dine-in and takeout, but customers will incur a $5 delivery fee plus a 5% service charge for this convenience.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40876180/darden-restaurants-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-mos" rel="noreferrer noopener"> Darden Restaurants Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
BMO Capital Markets: While the analyst expects the company to gain incremental benefits from delivery and views the deal structure positively, they wouldn&#8217;t be surprised if sales growth lags behind competitors due to potential overlap with its existing substantial off-premise business and its absence from the third-party marketplace. Currently, Strelzik forecasts a modest boost to Olive Garden&#8217;s comparable sales in the second half of 2025 and a low-single-digit increase in FY2026.
Wedbush: The analyst projects that DRI will continue to gain market share even in a challenging consumer landscape, suggesting a strong likelihood of achieving its long-term annual return targets. The analyst emphasizes the company&#8217;s on-demand delivery collaboration with Uber, starting with a pilot in 5-6 Olive Garden units. This will expand to approximately 100 units in FQ2 ahead of the holidays, eventually launching at all Olive Garden locations with curbside to-go by the end of FY25. The partnership is set up as a first-party delivery model, and there are no plans to advertise on UberEats.
Piper Sandler: According to the analyst, the Uber partnership will begin with Olive Garden, the company&#8217;s largest brand, accounting for about 45% of revenue and 50% of segment profit in Fiscal Year 2024. Given Olive Garden&#8217;s significance to the company&#8217;s financial model, this could lead to an unexpected boost in Darden&#8217;s adjusted EPS, especially in the following year, prompting a positive reaction in the stock today.
Truist Securities: The analyst is optimistic about the widespread improvement in same-store sales (SSS) across Darden&#8217;s portfolio since July. This, along with more proactive marketing efforts and easier year-over-year comparisons in the second half of FY25, enhances the analyst&#8217;s confidence that the accelerating SSS and market share gains will bolster Darden&#8217;s premium valuation.
Price Action: DRI shares are trading lower by 1.41% to $169.85 at last check Friday.
Photo: Courtesy of Dutchmen Photography via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40957191/this-pepsico-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday" target="_blank" rel="noreferrer noopener">This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

Equities

Darden's Uber Partnership Fuels Optimism, Analysts See Market Share Gains And EPS Boost In FY25

WIIM

America Movil shares are trading lower after Scotiabank lowered its price target on the stock from $18.9 to $17.8.

AMAT

Applied Materials shares are trading lower after Mizuho lowered its price target on the stock from $245 to $225.

TechnipFMC shares are trading higher after the company announced it was rewarded two contracts by the Petrobas for Brazil's pre-salt fields. The first contract is between $250 million to $500 million and the second is ranges from $75 million to $250 million.

Investors with a lot of money to spend have taken a bullish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $130,757, and 4 are calls, for a total amount of $147,345.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $125.0 for Starbucks over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Starbucks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale trades within a strike price range from $85.0 to $125.0 in the last 30 days. 
<h3>Starbucks 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857591_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$13.6</td>
<td>$12.4</td>
<td>$13.05</td>
<td>$85.00</td>
<td>$48.2K</td>
<td>614</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$95.00</td>
<td>$45.7K</td>
<td>8.1K</td>
<td style="text-align: right;">464</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$10.35</td>
<td>$9.75</td>
<td>$9.9</td>
<td>$85.00</td>
<td>$39.6K</td>
<td>550</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$5.75</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$100.00</td>
<td>$33.3K</td>
<td>3</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$12.35</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$100.00</td>
<td>$32.1K</td>
<td>103</td>
<td style="text-align: right;">105</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
Following our analysis of the options activities associated with Starbucks, we pivot to a closer look at the company's own performance.
<h3>Current Position of Starbucks</h3>
<ul>
<li>Trading volume stands at 5,259,380, with SBUX's price down by -0.09%, positioned at $96.81.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

SBUX

Check Out What Whales Are Doing With SBUX

High-rolling investors have positioned themselves bearish on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern.
The sentiment among these major traders is split, with 22% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $35,055, and 8 calls, totaling $278,552.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $87.5 for Gilead Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Gilead Sciences stands at 445.5, with a total volume reaching 2,234.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $75.0 to $87.5, throughout the last 30 days.
<h3>Gilead Sciences Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857586_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$75.00</td>
<td>$41.2K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.73</td>
<td>$75.00</td>
<td>$38.4K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">343</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.45</td>
<td>$8.8</td>
<td>$8.83</td>
<td>$75.00</td>
<td>$36.1K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">141</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.15</td>
<td>$6.15</td>
<td>$87.50</td>
<td>$35.0K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$75.00</td>
<td>$34.3K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">506</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,413,669, with GILD's price down by -0.71%, positioned at $83.31.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>What The Experts Say On Gilead Sciences</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $77.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Gilead Sciences with a target price of $74. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $70. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $95. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

GILD

Gilead Sciences Unusual Options Activity For September 20

Deep-pocketed investors have adopted a bearish approach towards AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in APP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for AppLovin. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 5 are puts, totaling $699,984, and 6 are calls, amounting to $278,842.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $140.0 for AppLovin, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AppLovin's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AppLovin's whale trades within a strike price range from $100.0 to $140.0 in the last 30 days. 
<h3>AppLovin Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857580_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.37</td>
<td>$110.00</td>
<td>$283.9K</td>
<td>640</td>
<td>416</td>
</tr>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.6</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$130.00</td>
<td>$182.2K</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$120.00</td>
<td>$168.0K</td>
<td>403</td>
<td>268</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.2</td>
<td>$27.5</td>
<td>$27.6</td>
<td>$105.00</td>
<td>$69.0K</td>
<td>1.8K</td>
<td>27</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.2</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$125.00</td>
<td>$56.2K</td>
<td>9.5K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About AppLovin</h3>
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.
In light of the recent options history for AppLovin, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is AppLovin Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,364,096, the price of APP is up by 1.23%, reaching $125.53.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 47 days from now.</li>
</ul>
<h3>Expert Opinions on AppLovin</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Buy rating on AppLovin, maintaining a target price of $155. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on AppLovin, which currently sits at a price target of $120. 
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Buy with a revised price target of $145. 
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on AppLovin, which currently sits at a price target of $150. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Sell rating for AppLovin, targeting a price of $66. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AppLovin options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On AppLovin

This week has been a bit down in general and in regards to the technology sector, particularly companies focused on <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence (AI),</a> has once again taken front and center stage in the stock market. Industry giants like Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), <a href="https://www.benzinga.com/quote/MSFT">Microsoft </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) have seen their stocks experience notable fluctuations, driven by a mix of optimism around AI&#8217;s potential and concerns over high valuations.
In recent months, AI has become one of the hottest trends on Wall Street. With tech companies integrating AI into various products and services, investors are eager to capitalize on this technological revolution. However, the enthusiasm is also being met with caution as analysts weigh the sustainability of current valuations and where this market my be headed. .
<h3 class="wp-block-heading">Nvidia&#8217;s Continued AI Boom Seems To Be Neverending</h3>
<h4 class="wp-block-heading">Strong Demand For AI Chips</h4>
One of the biggest players in the AI space, Nvidia, has been benefiting significantly from the high demand for its graphics processing units (GPUs). These chips are essential in powering advanced AI systems, including those used in machine learning and neural networks. Nvidia's position as a leader in AI chips has been solidified as companies and institutions increasingly adopt AI technologies and the need for companies to show they are utilizing advancements in AI is strong.
That being said, this surge in demand comes with its own set of challenges. While Nvidia's stock has soared throughout 2023, this week has seen increased volatility, which has lead to concerns about whether the company's stock price can continue to rise at such a rapid pace. Some analysts are beginning to voice caution, noting that the stock may be overvalued in the short term, even if the long-term outlook remains strong.
<h4 class="wp-block-heading">Valuation Concerns</h4>
Despite Nvidia's dominance, the company&#8217;s high stock price is attracting skepticism. Investors are concerned about whether Nvidia&#8217;s current valuation is justified or whether the stock has surged too far, too fast. Many see the current price as a reflection of market hype around AI rather than the company&#8217;s actual financial performance.
<h3 class="wp-block-heading">Microsoft and OpenAI partnership</h3>
<h4 class="wp-block-heading">Expanding AI Services</h4>
Microsoft is another tech giant that has ridden the AI wave, particularly through its investment in OpenAI, the company behind ChatGPT. Microsoft has not only integrated AI into its own product offerings but has also enabled other businesses to access powerful AI tools through its cloud services. As a result, <a href="https://www.benzinga.com/news/24/09/40931968/microsofts-linkedin-in-hot-water-for-allegedly-using-data-of-users-for-training-ai-before-updating-t">Microsoft's </a>stock has continued to perform well, benefiting from the excitement surrounding AI's practical applications in industries ranging from healthcare to finance.
<h4 class="wp-block-heading">Market Response</h4>
This week, Microsoft's stock has seen steady movement, driven by announcements of further AI integration into its cloud infrastructure and software services. Microsoft's dominance in both cloud computing and AI has put it in a position to lead the market, but as with Nvidia, there are concerns about whether the stock is overvalued due to AI hype.
<h3 class="wp-block-heading">Alphabet's Role in the AI Race</h3>
<h4 class="wp-block-heading">Google's AI Innovations</h4>
Not to be outdone, Alphabet (Google) is also a major player in the AI space. Google's work on AI technologies such as Google Bard and AI-driven search algorithms has kept the company in the spotlight. This week, Alphabet has faced a mix of optimism and caution. On one hand, the company is expected to remain a key player in AI for years to come. On the other, like Nvidia and Microsoft, Alphabet is grappling with regulatory concerns and skepticism about overvaluation.
<h4 class="wp-block-heading">Regulation And Oversight</h4>
The increasing reliance on AI has attracted the attention of governments worldwide. Alphabet, along with other tech giants, faces growing pressure to ensure that AI is developed and deployed responsibly. Concerns around data privacy, AI's potential to disrupt industries, and the ethical implications of AI-driven decision-making are hot topics. As a result, Alphabet's stock, while generally positive this week, has been influenced by regulatory discussions.
<h3 class="wp-block-heading">Conclusion: Volatility And Opportunity</h3>
This week's movements in AI stocks reflect the broader uncertainty in the tech market. While companies like Nvidia, Microsoft, and Alphabet are positioned to lead the AI revolution, investors must weigh the risks of overvaluation and the potential for regulatory changes against the long-term benefits AI is poised to deliver.
The story of AI in tech stocks is far from over, and as the technology continues to evolve, so too will the market's reaction. For now, both excitement and caution remain key themes in this rapidly developing space.

GOOGL

NVDA

The Ups And Downs Of AI Stocks This Week

Vistra shares are trading higher after BMO Capital raised its price target on the stock from $120 to $125. The stock is also moving higher in sympathy with the nuclear and uranium industry.

Insider Trades

GLMD

Masaya Otsuka Reported a 9.9% Passive Stake In Galmed Pharmaceuticals In A 13G Filing

ENFN

Enfusion shares are trading higher after the company announced it is interviewing investment banks to explore options including a potential sale.

It has been about a month since the last earnings report for Zoom Video Communications (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>). Shares have lost about 1.7% in that time frame, underperforming the S&amp;P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Zoom Video due for a breakout? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
<h3>Zoom Q2 Earnings Beat, Enterprise Customers Drive Revenues</h3>
Zoom&#39;s second-quarter fiscal 2025 adjusted earnings of $1.39 per share beat the Zacks Consensus Estimate by 14.88% and increased 3.73% year over year.
Revenues of $1.16 billion beat the consensus mark by 1.22% and increased 2.09% year over year on strong growth from Enterprise customers. Adjusting for foreign currency impact, revenues in constant currency were $1.166 billion, up 2.4% year over year.
<h3>Quarter Details</h3>
Enterprise revenues were $682.8 million, up 3.5% year over year and represented 58.7% of total revenues. Customers contributing more than $100,000 in revenues in the trailing 12 months grew 7% to 3,933. These customers accounted for 31% of revenues, up from 29% in the year-ago quarter.
In the fiscal second quarter, as part of an effort to improve the customer experience and drive greater efficiency in operations, the company transitioned 26,800 Enterprise customers with low annualized revenue run rate&nbsp;to Online.
The number of Enterprise customers at the end of the second quarter, after accounting for the transition, was approximately 191,600.
The company reported a trailing 12-month net dollar expansion rate for Enterprise customers of 98%.
As of the end of the quarter under review, the cumulative number of Zoom Rooms licenses purchased was more than 2 million.
In the quarter, Zoom saw amazing traction with Workvivo as it reached 69 customers with more than $100,000 in ARR, roughly doubling year over year. Workvivo was named Meta Platform&#39;s only preferred migration partner for its customers as it retires Workplace from Meta.
ZM witnessed additional traction in Zoom Contact Center as it surpassed 1,100 Zoom Contact Center customers, representing more than 100% year-over-year growth. This was driven by its recently launched higher pricing tiers as well as its success in larger deals.
The company now has five customers with 100,000 or more Zoom Phone seats. Zoom AI Companion has grown significantly with more than 1.2 million customer accounts enabled as of date.
<h3>Non-GAAP Operating Details</h3>
Non-GAAP gross margin in the fiscal second quarter was 78.6%, which was slightly lower than 80.3% in the year-ago period, mainly due to investments in AI innovation.
Research and development expenses increased 7.8% year over year to $206.7 million. Sales and marketing expenses declined 3.9% to $358.7 million, while general and administrative expenses plunged 15.3% to $109.5 million.
Operating income rose 13.9% to $202.37 million year over year. The operating margin came in at 17.6% compared with the year-ago quarter&#39;s operating margin of 15.9%.
<h3>Balance Sheet</h3>
Total cash, cash equivalents and marketable securities, as of Jul 31, 2024, were $7.5 billion.&nbsp; As of Apr 30, 2024, cash, cash equivalents and marketable securities were $7.4 billion.
Net cash provided by operating activities was $449.3 million for the fiscal second quarter, up 33.7% year over year. Free cash flow was $365.1 million, up 26.2% year over year.
<h3>Guidance</h3>
Zoom expects third-quarter fiscal 2025 revenues between $1,162 million and $1,165 million.
Non-GAAP earnings per share are expected in the range of $1.29-$1.31.
For fiscal 2025, Zoom expects revenues in the range of $4.63-$4.64 billion.
Non-GAAP earnings per share are expected in the band of $5.29-$5.32.
<h2>How Have Estimates Been Moving Since Then?</h2>
It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 12.46% due to these changes.
<h2>VGM Scores</h2>
At this time, Zoom Video has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.
<h2>Outlook</h2>
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Zoom Video has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
<h2>Performance of an Industry Player</h2>
Zoom Video is part of the Zacks Internet - Software industry. Over the past month, HubSpot (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hubs#NYSE">HUBS</a>), a stock from the same industry, has gained 6.7%. The company reported its results for the quarter ended June 2024 more than a month ago.
HubSpot reported revenues of $637.23 million in the last reported quarter, representing a year-over-year change of +20.4%. EPS of $1.94 for the same period compares with $1.34 a year ago.
For the current quarter, HubSpot is expected to post earnings of $1.89 per share, indicating a change of +18.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for HubSpot. Also, the stock has a VGM Score of B.
<a href="https://www.zacks.com/stock/news/2339316/zoom-video-zm-down-1-7-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-2339316">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Guidance

HUBS

Zoom Video Down 1.7% Since Last Earnings Report: Can It Rebound?

Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) has outperformed the market over the past 20 years by 4.48% on an annualized basis producing an average annual return of 12.97%. Currently, Equifax has a market capitalization of $37.39 billion. 
Buying $1000 In EFX: If an investor had bought $1000 of EFX stock 20 years ago, it would be worth $11,290.99 today based on a price of $302.19 for EFX at the time of writing.
<h3>Equifax's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857087_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today

Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) has outperformed the market over the past 20 years by 16.43% on an annualized basis producing an average annual return of 24.91%. Currently, Deckers Outdoor has a market capitalization of $22.82 billion. 
Buying $1000 In DECK: If an investor had bought $1000 of DECK stock 20 years ago, it would be worth $85,940.67 today based on a price of $149.68 for DECK at the time of writing.
<h3>Deckers Outdoor's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857082_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DECK

Here's How Much $1000 Invested In Deckers Outdoor 20 Years Ago Would Be Worth Today

Despite a wider market pullback, the <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40930136/expert-says-the-future-of-defi-will-be-shaped-by-fintechs-like-revolut-and-robinhood-not-w">total value locked (TVL) in DeF</a>i on Core (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CORE</a>), Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Layer-2 blockchain, has grown significantly in the second quarter of 2024.
What Happened: According to a Messari report, Core&#8217;s DeFi TVL grew by 1,032% in Q2, reaching $76.4 million. The blockchain&#8217;s native decentralized exchange (DEX) CoreX outperformed SushiSwap, a multi-chain DEX.
Non-custodial bitcoin staking, launched on Core's platform in April, saw 3,504 BTC, equivalent to $215 million, staked in Q2, broadening investor access and exposure to Core.
Valour, a subsidiary of DeFi Technologies, introduced a unique yield-bearing Core BTC exchange-traded product (ETP) to German investors on the Frankfurt stock exchange in June. This initiative offers users a 5.65% yield in addition to Bitcoin exposure.
Core and Valour have since listed other BTC ETPs on Sweden's Spotlight Stock Market and the London Stock Exchange.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40734905/blockchain-core-foundation-launches-liquid-staking-token-pegged-against-bitcoin">Blockchain Core Foundation Launches Liquid Staking Token Pegged Against Bitcoin</a>
Why it Matters: Secured by and aligned with Bitcoin, Core&#8217;s blockchain is unlocking over $1.25 trillion in trapped Bitcoin liquidity. The platform hosts over 100 Dapps, enabling Bitcoin holders to utilize their Bitcoin in innovative ways.
The significant growth in DeFi TVL and the introduction of non-custodial BTC staking underscore Core&#8217;s commitment to providing diverse investment opportunities and enhancing investor access. 
The listing of BTC ETPs on various stock exchanges also reflects Core&#8217;s expanding global presence and its efforts to offer investors yield-bearing opportunities in addition to Bitcoin exposure.
Rich Rines, an Initial Contributor to Core, noted that demand for Bitcoin staking and Core DeFi is increasing, commenting, &#8220;The first quarter with live Non-Custodial Bitcoin Staking represents a new epoch for Bitcoin, powered by Core.&#8221; 
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40961891/blockchains-global-expansion-insights-from-an-interview-with-korea-blockchain-weeks-founde">Blockchain&#8217;s Global Expansion: Insights From An Interview With Korea Blockchain Week&#8217;s Founder</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$CORE

Core Blockchain's DeFi TVL Skyrockets Over 1000%, Introduces Non-Custodial BTC Staking

Orexo AB reports Q3 interim results

Orexo AB GAAP EPS of -SEK0.54, revenue of SEK166M

Orexo AB reports Q1 results

Orexo AB GAAP EPS of -SEK1.04, revenue of SEK154M

Press Releases

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Report from Orexo AB's annual general meeting, 26 April 2024

Orexo Q1 2024 Interim Report

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Orexo: invitation to presentation of the Q2 2024 Interim Report

Orexo AB's sustainability work ranked among top 5% by EcoVadis

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

Orexo Q2 2024 Interim Report

Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024

Orexo

The&nbsp;<a class="editor-rtfLink" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-risks-dental-problems-associated-buprenorphine-medicines-dissolved-mouth-treat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA warned patients and prescribers</a>&nbsp;about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.

<ul>
	<li>The agency said the opioid addiction treatment had been reported to cause tooth decay, infection, and, in some cases, total tooth loss in patients with no history of dental issues.</li>
	<li>The buprenorphine medicines that are associated with dental problems are tablets dissolved under the tongue and films placed against the inside of the cheek.</li>
	<li>The FDA approved buprenorphine as a tablet in 2002 and as a film in 2015.</li>
	<li>It said patients might lessen their risk by taking preventative measures.</li>
	<li>After the product is completely dissolved, patients should take a large sip of water, swish it gently around their teeth and gums, and swallow, waiting for at least one hour before brushing their teeth after using the product to avoid damage to the teeth.</li>
	<li>The regulator&#39;s approved buprenorphine products include&nbsp;Orexo AB&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/orxof#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ORXOF</a>) Zubsolv and&nbsp;Indivior Plc&#39;s&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/invvy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">INVVY</a>) Suboclade.</li>
</ul>

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus&rsquo; spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.

The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets.

&ldquo;They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping,&rdquo; he said. &ldquo;The life science business is certainly continuing.&rdquo;

In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">Virtual Life Science Investor Forum</a> on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments.

&ldquo;Certainly with what&rsquo;s going on with the coronavirus pandemic, it just makes it that much more relevant,&rdquo; said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. &ldquo;The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities.&rdquo;

According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series.

&ldquo;It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention,&rdquo; Paltrowitz said of this week&rsquo;s conference. &ldquo;And we thought being able to host a series of virtual conferences would help.&rdquo;

Below is the schedule for the conference. Each presentation is followed by a virtual Q&amp;A session with attendees and is available on demand.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

9:30 AM ET RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) 
Speaker: Guy Goldberg, Chief Business Officer 
About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill&rsquo;s recently FDA approved drug, Talicia&reg;. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.

10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NRIFF#OTCQX">NRIFF</a>) 
Speakers: Jesse Ledger, President &amp; Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer 
About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company&#39;s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

10:30 AM ET Orexo AB (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORXOY#OTCQX">ORXOY</a>) 
Speaker: Nikolaj S&oslash;rensen, President &amp; CEO 
About: Orexo develops improved pharmaceuti&shy;cals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv&reg; for treatment of opioid use disor&shy;der.

11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQB">EMMA</a>) 
Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood 
Chief Financial Officer

About: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari&reg; (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

11:30 AM ET Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) 
Speaker: Walter Klemp, Founder, President, CEO &amp; Chairman 
About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company&#39;s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

12:00 PM ET Lexaria Bioscience Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LXRP#OTCQX">LXRP</a>) 
Speaker: Chris Bunka, CEO 
About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH&trade; drug delivery technology changes the way API&#39;s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

12:30 PM ET Beroni Group Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BNIGF#OTCQX">BNIGF</a>) 
Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO 
About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection &amp; diagnosis of infectious diseases.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

Photo by&nbsp;<a href="https://unsplash.com/@thisisengineering?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">ThisisEngineering RAEng</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/laboratory?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Orexo

News

Latest news for Orexo (OTC:ORXOY) Stock

Thursday, January 13, 2022

Wednesday, March 25, 2020